SCHEMBL5259057

SCHEMBL5259057

N#Cc1cc(C(=O)c2ccc(F)cc2)n2c1ccc1c(Cl)cccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NR3C2 P08235 4/20 0.37
▸ NR3C1 P04150 1/20 0.37
▸ FNTA P49354 4/20 0.37
▸ FNTB P49356 4/20 0.37
▸ FASN P49327 1/20 0.37
▸ RORC P51449 2/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ CDC25A P30304 1/20 0.36
▸ DUSP3 P51452 1/20 0.36
▸ AR P10275 1/20 0.35
▸ HSD11B1 P28845 1/20 0.34
▸ KCNJ5 P48544 1/20 0.34
▸ KCNJ3 P48549 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5311850 0.90 PTPN1 (0.43) FNTAFNTBPTPN1CDC25ADUSP3
SCHEMBL5313502 0.81 LMNA (0.41) KDM4EMEN1LMNAMAPTHTT
SCHEMBL5259574 0.81 HTR2A (0.41) KDM4EMEN1LMNAMAPTHTT
SCHEMBL18333468 0.81 PTPN1 (0.34) KDM4EMEN1MAPTHTTKMT2A
SCHEMBL5259688 0.77 PTPN1 (0.44) FNTAFNTBPTPN1CDC25ADUSP3
SCHEMBL5309491 0.75 LMNA (0.41) KDM4EMEN1LMNAMAPTHTT
SCHEMBL5959251 0.74 FNTA (0.44) MEN1MAPTKMT2ASMN1; SMN2FNTA
SCHEMBL5259774 0.74 LMNA (0.39) KDM4EMEN1LMNAMAPTHTT
SCHEMBL5259114 0.72 PTPN1 (0.41) MAPTHTTFNTAFNTBPTPN1
SCHEMBL5310989 0.71 PTPN1 (0.44) KDM4ELMNAMAPTFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US claimed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US claimed
EP-1578424-A4 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA INC (US) 2007-08-08 — — EP disclosed
US-7135480-B2 Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers CYTOVIA, INC. (US) 2006-11-14 — — US disclosed
EP-1578424-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS Cytovia, Inc. (US) 2005-09-28 — — EP disclosed
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2005-01-20 — — US disclosed
WO-2004055163-A2 SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES CYTOVIA, INC. (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014759-A1 Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis CASP3, CASP7, CASP1 KDM4E 570/4885MEN1 2503/4885LMNA 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback